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In this thesis a number of individual studies are presented concerning
treatment, and prognostic aspects of young patients with poor-risk
aggressive lymphomas. Although these studies contain several
overlapping and parallel issues, the disparities in clinical presentation,
treatment, prognostic factors and outcome of distinct lymphoma entities
are substantial. Therefore, the chapters in this thesis have been grouped
according to the main lymphoma type addressed in the separate studies,
i.e. diffuse large B-cell lymphoma, Burkitt lymphoma, and post-
transplant lymphoproliferative disorder – also called post-transplant
lymphoma –, respectively. In addition, prognostic factors related to
outcome in relapsing aggressive lymphoma are presented. Accordingly,
the summary and discussion follow this grouping.
Chapter 2 Diffuse large B-cell lymphoma
In chapter 2.1 and 2.2 the results are presented of dose-intensified chemother-
apy treatment in diffuse large B-cell lymphoma. When these HOVON (stichting
Hemato-Oncologie voor Volwassenen Nederland) studies were initiated, 8 cycles
of CHOP-21 (cyclophosphamide, hydroxyldaunomycin, vincristine, prednisone)
three-weekly was considered the standard of treatment.1 Our main question was
whether treatment results could be improved by intensifying chemotherapy. The
rationale for these studies was based on the favorable results of high-dose
chemotherapy followed by autologous stem cell transplantation (ASCT) in
patients with relapsed aggressive lymphoma (PARMA) and the importance of
cyclophosphamide and doxorubicin dose for outcome in aggressive lymphoma.2
Short of autologous stem cell support, intensification of CHOP-21 had not
been very successful.3 The introduction of G-CSF (granulocyte colony stimulat-
ing factor) provided the possibility to escalate the CHOP-21 regimen, without
the use of autologous stem cell support. The IPI (International Prognostic Index)
had not been published yet, therefore patients with aggressive lymphoma were
stratified into low, intermediate or high-risk, according to the previously defined
HOVON risk profile.4 Patients with high-risk, who according to this HOVON risk
stratification had an expected survival of only 24% at 5 years, were enrolled into
two consecutive phase II trials (HOVON-27 and -40) with front-line high-dose
chemotherapy and ASCT, described in chapter 2.1. For patients with interme-
diate-risk, who had an expected 5 year survival of 49% according to HOVON risk
criteria, a randomized phase III was initiated that compared intensified-CHOP
to CHOP-21 (HOVON-26), described in chapter 2.2.
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Chapter 2.1 Up-front ASCT in poor risk DLBCL, HOVON trials 27 and 40
The results of the first trial (HOVON-27) with up-front ASCT were disap-
pointing. Outcome of this trial, which consisted of two high-dose induction
courses of chemotherapy followed by ASCT, did not differ from a historical cohort
of patients with the same risk factors treated with 8 cycles of CHOP-21. Based on
the analysis of this HOVON-27 trial and the available literature that reported
conflicting results of up-front ASCT at that time, it was hypothesized that a more
robust induction treatment before ASCT, containing a higher cumulative dose
of cyclophosphamide and doxorubicin might improve outcome. Our subsequent
HOVON-40 trial tested this hypothesis by adding 3 courses of intensified CHOP
to the induction treatment, which was otherwise equal to trial HOVON-27. The
results of this strategy were remarkable, resulting in a marked improvement in
event free, progression free and overall survival in the HOVON-40 trial com-
pared with the HOVON-27 trial.5 We concluded from these consecutive studies
that ASCT as front-line treatment in high-risk patients with diffuse large B-cell
lymphoma is more successful after a robust induction treatment, i.e. – in the case
of the HOVON-40 schedule – treatment with a sufficient amount of dose-dense
cyclophosphamide and doxorubicin. Nevertheless, 25% of patients still failed to
respond to induction treatment. Thus, reducing the number of primary refrac-
tory patients remains an important goal of current and future clinical studies in
high-risk diffuse large B-cell lymphoma. This refractoriness will probably not
be amenable to further chemotherapy manipulation, because the proportion of
refractory patients in HOVON-27 and -40 was not different.
Overcoming primary resistance by adding (radio-)immunotherapy to
chemotherapy, e.g. rituximab, will be the obvious next step in ameliorating treat-
ment results. The addition of rituximab to chemotherapy schedules may sub-
stantially reduce the fraction of patients with primary refractory disease.6,7
Although rituximab was found to be active in combination with CHOP in all IPI
risk classes in the elderly,6 and the IPI remained relevant as risk classifier in low
risk young patients treated with rituximab,7 it remains to be determined whether
rituximab will be equally effective in young patients with high-risk disease, such
as those with advanced disease and highly elevated LDH levels included in our
HOVON-27 and 40 trials. Moreover, highly elevated LDH levels may confer addi-
tional risk beyond the IPI for outcome.8 Thus, despite the expected strong effects
of rituximab, there might still be a place for up-front ASCT in patients with poor-
risk diffuse large B-cell lymphoma. Obviously, it remains to be determined
whether, and if so, which patients will benefit from this strategy when rituximab
is added to high-dose treatment schedules. Several prospective studies are cur-
rently comparing R-CHOP-like therapy to R-high-dose treatment followed by
ASCT in poor-risk patients. Similarly, HOVON is conducting a prospective ran-
domized study, comparing R-CHOP with an up-front ASCT regimen, based on
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the HOVON-40 with the addition of rituximab in intermediate-high and high-
risk age-adjusted IPI (aa-IPI) patients (HOVON-63).
Chapter 2.2 Intensiﬁed-CHOP-14 v. CHOP-21 in patients with
intermediate-risk aggressive NHL (HOVON-26)
In chapter 2.2 the effect of doubling the dose intensity of cyclophosphamide
and doxorubicin on outcome was investigated in patients with intermediate-risk
aggressive lymphoma according to HOVON risk criteria. In this trial, the cumu-
lative doses of the aforementioned drugs were the same, but the fractional dose
of chemotherapy per cycle in the experimental, so called intensified-CHOP-14
arm was increased and delivered in 12 weeks instead of 24 weeks in the standard
CHOP-21 arm. With G-CSF support the planned dose could be attained in 70%
of the patients in both arms of the study and the median increment of actual
delivered dose intensity, of doxorubicin and cyclophosphamide in the intensified
CHOP-14 arm was almost twice that of the CHOP-21. However, no significant
improvement in outcome of patients treated according to the intensified CHOP
arm was observed.
Hypothesis-generating subgroup analysis indicated a possible improvement
in FFS for patients with low or low-intermediate aa-IPI. However, these results
must be interpreted with caution, because the trial was not powered for this sub-
group analysis. Fortunately, the results of our subgroup analysis are supported
by the German B1 study, in which CHOP-14 was better than CHOP-21 in patients
with low, low-intermediate aa-IPI risk aggressive NHL.9 In addition, a 2 weekly
CHOP schedule, although more toxic at least in case of intensified CHOP-14, will
shorten the total duration of treatment substantially. Taken together, dose-dense
CHOP either as CHOP-14 or intensified CHOP-14 may be the preferred
chemotherapy in combination with rituximab in treatment for young patent with
low or low-intermediate aa-IPI aggressive lymphoma. For patients with higher
risk profiles chemotherapy intensification of this order of magnitude is apparently
not sufficient. These patients might indeed be candidates for strategies incorpo-
rating up-front high-dose therapy and ASCT.5,10
Both intensification of CHOP as well as the addition of rituximab may
improve results in elderly patients of all IPI risks, as well as young patients with
low, low-intermediate risk DLBCL.6,7,9,11 In elderly patients, preliminary results
from HOVON indicate that R-CHOP-14 is also superior to CHOP-14.12,13 Thus,
available evidence indicates that the additive effect of rituximab is independent
of chemotherapy dose. Obviously, the question still to be answered is: will R-
CHOP-14 or R-intensified-CHOP-14 be better than R-CHOP-21? This question
will hopefully be answered by the French lymphoma group, which is currently
comparing 8 cycles of R-CHOP-14 with R-CHOP-21 in elderly patients.
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Furthermore, the addition of rituximab to dose-dense chemotherapy has also
reopened the debate about the total amount of chemotherapy cycles necessary
for cure. This debate has been fuelled by excellent results of 6 cycles of R-CHOP-
21 combined with radiotherapy in young patients with low-risk disease in the
MINT trial,7 and preliminary data from a recently completed DSGHL-trial
(RICOVER) comparing 6 cycles of CHOP-14 with 8 cycles of CHOP-14 each com-
bined with, or without rituximab, in elderly patients with diffuse large B-cell
lymphoma. The latter trial contained a direct comparison between 6 or 8 cycles
of CHOP-14. After a median observation time of 26 months, there was a trend for
better freedom from treatment failure after 8 cycles of CHOP-14 compared to 6
cycles of CHOP-14 (58% v. 53%; p=0.13), but this trend was neutralized after the
addition of rituximab: 70% for both 6 and 8 cycles R-CHOP-14.13 Although an
impressive number of patients (n=1330) have been included in this trial, and it
was powered to detect a 9% freedom from treatment failure at 3 years, follow-up
is still short and these data need further maturation before more definite con-
clusions are possible. More importantly, the question whether 6 cycles of R-
CHOP-14 alone will be sufficient for cure will not be answered by this trial,
because additional radiotherapy was administered to patients with bulky and
extranodal sites of disease, as has been the case in other trials of the DSGHL
comparing six cycles of CHO(E)P-14 with CHO(E)P-21.9,11 Of note, the ongoing
French study mentioned before is comparing 8 cycles of R-CHOP-14 with R-
CHOP-21 without the additional use of radiotherapy. It will be very difficult to
compare the efficacy and, moreover, potential late toxicity (such as in-field sec-
ondary tumors and vascular damage) introduced by the consolidation radio-
therapy after 6 CHOP cycles, versus the addition of 2 extra CHOP cycles.
Furthermore, chemotherapy seems to be less safe, as far as late toxicity is con-
cerned, than previously assumed. A recent study by the EORTC based upon a
large series of patients with aggressive NHL treated with 8 CHOP-like courses,
showed impressive late cardiotoxicity, undoubtedly related to ‘normal’ (i.e. not
exceeding the cumulative dose of 400 mg/m2) dose of adriamycin given.14
Chapter 2.3 Prognostic signiﬁcance of germinal center associated
proteins and chromosomal breakpoints in poor-risk diffuse large B-
cell lymphoma
Apart from the IPI, intrinsic biological aspects of the tumor also play a role
in prognosis. Although many studies have focused on the significance of intrin-
sic characteristics of the tumors, e.g. protein or gene expression and chromoso-
mal breakpoints, the clinical relevance of many of these markers is inconsistent.
Moreover, few markers retain sufficient prognostic significance independently
when adjusted for the overriding prognostic impact of the IPI risk score. Gene
expression analysis enables subclassification of diffuse large B-cell lymphoma
Secondary IPI and outcome after ASCT in NHL
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into tumors with an expression pattern resembling that of B-cells of the normal
germinal center (GCB) or an expression pattern more resembling that of acti-
vated, post-germinal center B-cells, also called non-germinal B-cells (non-GCB).
Patients with tumors exhibiting non-GCB gene expression have worse survival
than those with tumors exhibiting GCB gene expression.15 Importantly, this effect
is independent from IPI risk factors in patients treated with CHOP-like ther-
apy.16 Moreover, similar grouping can be achieved by using a simple algorithm,
combining the expression of CD10, bcl6 and MUM1 by immunohistochemistry.17
In chapter 2.3 we investigated whether the prognostic value of GCB versus
non-GCB diffuse large B-cell lymphoma would also be present in a homoge-
neous group of patients with poor IPI risk, treated with high-dose therapy and
ASCT as first-line treatment. In addition, we also analyzed the prognostic value
of different chromosomal breakpoints. We could confirm the prognostic value
of GCB v. non-GCB immunophenotype in our group of patients. In addition,
based on analysis of the prognostic value of the individual markers, we argued
that a higher cut-off value for MUM1/IRF4 might improve the negative predic-
tive value of this marker and the performance of the algorithm.18
Chromosomal breakpoints did not seem to confer additional prognostic
impact. However, given the number of patients analyzed, clinically relevant dif-
ferences might still be present when analyzed in larger groups of patients. The
adverse prognostic impact of bcl2 protein expression reported by others was con-
firmed. This effect was present both in GCB as well as in non-GCB tumors.
Apparently, this adverse effect on prognosis associated with bcl2 was inde-
pendent of the mechanism leading to over-expression, i.e. chromosomal translo-
cation of the BCL2 gene t(14;18), found in the majority of GCB tumors, or other
mechanisms leading to bcl2 over-expression in non-GCB tumors.
Our findings confirm the prognostic value of the immunophenotype in
DLBCL and extend these finding to patients with poor-risk disease treated with
high-dose chemotherapy and ASCT. Future studies will have to determine,
whether the prognostic value of this algorithm will keep its predictive value for
prognosis in patients treated with rituximab. For instance, rituximab seems to
have higher efficacy in tumors with bcl2 overexpression,19 a marker independ-
ently associated with worse prognosis in patients treated without rituximab. Thus,
although the prognostic value of individual markers may be transient in the light
of changing treatment paradigms, gene-expression studies in lymphoma are of
great importance for unraveling histopathogenesis and guiding new treatment
modalities in malignant lymphoma. Therefore, the retrieval of adequate (frozen)
tumor material and construction of tissue microarrays in clinical studies is of
utmost importance.
6  Summary and general discussion
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Chapter 3 Burkitt lymphoma
Chapter 3.1 Short intensive sequential therapy and ASCT in adult
Burkitt lymphoma
In adults, this highly aggressive lymphoma is very rare and treatment not
well defined. Treatment according to protocols usually employed for treatment
of diffuse large B-cell lymphoma, such as CHOP chemotherapy, are not effective
in Burkitt lymphoma. Its high growth fraction, presentation at extranodal sites
and increased incidence of meningeal dissemination necessitate high-dose treat-
ment regimens combined with central nervous system prophylaxis. These regi-
mens, which are highly successful in children, are also effective in adults, but
more toxic.
Based on promising results from of ASCT in patients with aggressive lym-
phoma in first remission, including Burkitt lymphoma, we decided to investigate
the feasibility and efficacy of up-front ASCT in adult patients with advanced
non-leukemic Burkitt lymphoma. The treatment protocol (HOVON-27BL) was
similar to that of patients with high-risk diffuse large B-cell lymphoma included
in the HOVON-27 protocol (see chapter 2.1). In contrast to patients with diffuse
large B-cell lyphoma, in whom this very short high-dose treatment protocol was
ineffective, the results in adult patients with Burkitt lymphoma were excellent
and competitive to that of high-dose pediatric treatment regimens.20 However,
it must be stressed that we only included patients without meningeal disease or
bone marrow dissemination. The efficacy of our treatment protocol in patients
with extensive bone marrow involvement is unknown.
Comparison in a phase III setting of our ASCT-based regimen with a pedi-
atric regimen in adult patients with Burkitt lymphoma would be the obvious next
step. For patients with meningeal involvement we could combine our HOVON-
27 protocol with more intensive intraventricular chemotherapy via an Ommaya
reservoir.21 However, the rareness of Burkitt lymphoma in adults and the excel-
lent results of our own, as well as other current treatment strategies would neces-
sitate a large intergroup consortium to accrue sufficient patients for the detec-
tion of differences. In the mean time, the addition of rituximab to these regimens
has even further increased cure rates, making the feasibility of conducting such
a trial not very realistic.
Chapter 3.2 Gender and age related differences in Burkitt
lymphoma in The Netherlands
Based on histological, immunophenotypical and genetic data Burkitt lym-
phoma is considered to be a single disease entity. However, the striking differ-
ences in absolute and relative incidence – as compared to other lymphoma types –
of Burkitt lymphoma in children and adults, made us wonder whether Burkitt
lymphoma in children and adults should not be considered different diseases.
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We started with an analysis of differences in incidence and clinical charac-
teristics of sporadic Burkitt lymphoma in adults and children in The Netherlands.
For epidemiological reasons, incidence data of BL in The Netherlands, as clas-
sified by morphological data by the local pathologist, were retrieved from the
National Cancer Registry. Unfortunately, this registry does not contain sufficient
clinical data for analysis of disease extent at presentation. Therefore, differences
in clinical characteristics between adults and children with Burkitt lymphoma
were analyzed by comparing adult patients included in the HOVON-27 study
with children treated in SKION/SNWLK protocols during the same time frame.
In addition, in contrast to the epidemiological data, a very strict pathological def-
inition of Burkitt lymphoma was required for patients included in the compari-
son of clinical characteristics from both the SKION and HOVON database, includ-
ing the presence of a MYC/8q21 breakpoint in cases with atypical cytological
features, or so-called atypical Burkitt lymphoma.
A striking male preponderance was seen at all ages for Burkitt lymphoma
recorded in the national cancer registry, suggesting a possible difference in
genetic background of the disease in male as opposed to female patients. In addi-
tion, in male patients a bimodal age incidence was found with a peak at pediatric
age and a steady increase after 60 years, supporting the hypothesis of the exis-
tence of two disease entities for the different age groups. In contrast, the inci-
dence in female patients was stable in all age categories. The major difference
in clinical presentation of Burkitt lymphoma between children and adults was the
frequency of extranodal disease, which was more frequently observed in child-
hood Burkitt lymphoma.
A major limitation of the epidemiological analysis is the absence of histolog-
ical review of the registry data. This may have created bias especially in adults,
because there may be a substantial gray zone between Burkitt lymphoma and
diffuse large B-cell lymphoma in adults.22 As for the comparison of clinical char-
acteristics at presentation, bias could have been created because patients were
selected, based on the same criteria as used for entry in the HOVON-27 trial.
Only patients younger than 66 years were included and patients with CNS dis-
ease, extensive bone marrow dissemination, or bad performance status were
excluded. This led to the exclusion of 25% of childhood Burkitt lymphoma cases
in the SKION database. The incidence of patients with these characteristics in the
adult population is unknown and might be different. Nevertheless, despite the
constraints of these analyses, the hypothesis that Burkitt lymphoma at least in
male patients might consist of two different diseases is still tenable.
Because Burkitt lymphoma can also be classified based on specific gene
expression profiles,23,24 analyzing differences in gene expression of Burkitt lym-
phoma in (male) children and adults might be an other way to further investigate
our hypothesis.
6  Summary and general discussion
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Chapter 4 Post-transplant lymphoma
Post-transplant lymphomas (PTLD) are lymphomas developing in recipients of
solid organ or bone marrow transplantation. Most of these lymphomas are of B-
cell origin and contain EBV (Epstein Barr virus). Immunosuppressive treatment
to prevent allograft rejection leading to diminished T-cell surveillance, may give
rise to an unchecked EBV driven B-cell proliferation ultimately leading to lym-
phoma. These lymphomas often present at extranodal sites, including the allo-
graft, are sometimes difficult to diagnose, and may behave very aggressively.
Even with rituximab treatment mortality is high. We analyzed the clinical char-
acteristics, treatment, outcome and prognostic factors of patients with these lym-
phomas observed in recipients of kidney or lung transplants between 1985 and
2002 in our hospital.
Chapter 4.1 Early PTLD is localized in the allograft
The incidence, clinical characteristics at presentation, treatment outcome
and prognostic factors of PTLD were analyzed in a large cohort of kidney and
lung transplant recipients in the UMCG. Forty patients with histological con-
firmed PTLD were observed in a cohort of 1354 kidney and 206 lung transplant
recipients, who had been transplanted between 1985 and 2002. Lung transplant
recipients had higher incidence rates of PTLD than did kidney transplant recip-
ients (8.3% v. 1.7%), probably related to higher doses of immunosuppressive
treatment in the lung transplant recipients. Extranodal presentation occurred in
73% of the patients including allograft localization. Half of the PTLD occurred
within one year after transplantation. The allograft was significantly more fre-
quently involved as primary site of PTLD presentation during the first year after
transplantation. In multivariate analysis, predictive factors remaining significant
for outcome of PTLD treatment were: performance status and advanced stage
for response, and performance status for survival, respectively.
The results of this analysis are of course limited because they are not cor-
rected for treatment modality, which has changed over time during the observa-
tion period. As soon as rituximab became available we have treated all patients
with this monoclonal antibody. It may well be that prognostic factors of rele-
vance for treatment outcome of PTLD before rituximab became available, will be
less or no longer relevant after its introduction. Of the 14 consecutive patients
treated with rituximab in our cohort, 12 patients (86%) had a complete response,
which is higher than the 45% complete response rate reported recently in a
prospective study of rituximab treatment in 43 PTLD patients.25 Interestingly,
in the latter cohort of patients only elevated LDH level remained as prognostic
adverse factor for response.
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The most interesting finding was our observation of the association between
allograft localization and early PTLD. One could speculate that these lymphomas
might be partially donor-derived, i.e. originated from donor lymphocytes trans-
planted with the allograft. However, this hypothesis will not suffice because most
PTLD’s, including those localized in the allograft, are recipient-derived. In con-
trast, we speculate that the microenvironment of the allograft may play a per-
missive role in the development of PTLD.26 The intriguing association between,
recipient derived EBV positive B-cells, decreased immune response, allograft
microenvironment, HLA match and PTLD development needs further study.
Chapter 4.2 FDG-PET in PTLD
Given the excellent results of FDG-PET as tool in staging and treatment eval-
uation of malignant lymphoma, we also analyzed the applicability of FDG-PET
(18-fluorodeoxyglucose positron emission tomography) in PTLD. Although the
series of patients analyzed was small, all PTLD lesions studied were highly FDG
avid. Extranodal localizations of PTLD, which are frequently present but often
difficult to detect by conventional CT scanning, were easily detected by FDG-
PET. Disappearance of PET positive lesions after treatment correlated well with
freedom from PTLD recurrence. Thus, as is the case in diffuse large B-cell lym-
phoma, PET-FDG is also an excellent tool for staging and treatment evaluation
in PTLD.
Chapter 5 Relapsed aggressive lymphoma
Young patients with aggressive lymphoma who relapse after-, or are primary
refractory to first-line treatment can be salvaged by ASCT, provided their disease
is still responsive to salvage chemotherapy.27,28 The latter is usually defined as:
at least a partial response, based on conventional diagnostic methods, including
a CT-scan. However, only half of the patients who have failed first-line treat-
ment will be responsive and of those 50% will be cured by ASCT.27 To improve
upon these results, better parameters are required for the prediction of response
and cure. To this end, we investigated the prognostic value of clinical factors and
early FDG-PET defined response in two cohort studies of young patients with
relapsed chemosensitive lymphoma who were treated with ASCT.
Chapter 5.1 Prognostic value of secondary age-adjusted IPI
We analyzed the prognostic value of the age-adjusted IPI at relapse in a
cohort study of 88 young patients with NHL failing first-line CHOP-like treat-
ment, and who were treated with ASCT in our hospital between 1989 and 2002.
The secondary age-adjusted IPI (2nd-aa-IPI) proved to be highly predictive for
outcome in these patients who were still chemosensitive, i.e. responded to sal-
6  Summary and general discussion
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vage chemotherapy based on CT findings, and were subsequently treated with
ASCT.
Our study included patients with different duration of response to, and even
patients with less than partial response to first-line treatment. The quality as
well as duration of response to first-line chemotherapy are of predictive value for
response to salvage chemotherapy.27,29 However, in keeping with the finding of
others,30 in patients who responded to salvage chemotherapy, quality and dura-
tion of response to first-line treatment were no longer of significance for out-
come after ASCT in our analysis.
Our cohort contained not only patients with DLBCL, but also a substantial
number of patients with other histologies. Although these subgroups were obvi-
ously too small for definite conclusions, our results indicate that the 2nd-aa-IPI
might also have prognostic value in chemosensitive patients with other histolo-
gies.31
A limitation of this study is the fact that patients were selected based upon
chemosensitivity, i.e. post-hoc determined response based on CT scanning after
two courses of salvage induction treatment. Many patients received their sec-
ond-line induction chemotherapy outside the UMCG, and were only referred for
the transplant procedure if considered chemoresponsive. Therefore, we lacked
data on the characteristics of those patients who had failed second-line treat-
ment in this time frame. We estimate that this cohort contained approximately
half of all young patients failing first-line chemotherapy, given the approximately
50% response rate to salvage chemotherapy usually observed in these patients in
that time frame.27 This means that the patient population will indeed have been
selected and 2nd-aa-IPI might not necessarily have the same predictive value in
those not responding to second-line treatment. However, our primary objective
was to find prognostic factors in a population of patients selected on the basis of
primary eligibility for ASCT, i.e. responding disease as proven by at least partial
response after second-line chemotherapy, based on conventional diagnostic
methods (CT scan). In addition, after the first report of our data (ASH 2002) the
value of the 2nd-aa-IPI was confirmed in a large cohort of 150 DLBCL patients
from New York,30 both in all patients as well as in chemosensitive patients only.
Thus, it may be concluded that the 2nd-aa-IPI is of prognostic importance in
all patients, as well as in chemosensitive patients only. Moreover, our results as
well as those of others indicate that chemosensitivity and 2nd-aa-IPI are both
important and independent prognostic factors for outcome of ASCT in patients
with DLBCL who failed first-line treatment. Hence, in addition to determining the
2nd-aa-IPI, the early detection of patients with insufficient response to salvage
treatment is important in order to determine which patients might need modi-
fied salvage treatment.
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Chapter 5.2 Predictive value of early FDG-PET in chemosensitive
relapsed lymphoma
In this chapter we addressed the question of better defining early response
by analyzing the predictive value of midtreatment FDG-PET for outcome after
ASCT in patients who had failed first-line treatment for aggressive non-
Hodgkin’s and Hodgkin lymphoma. Half of the patients with apparent respon-
sive disease, again classified by conventional criteria based on CT scanning, ulti-
mately relapsed after ASCT. From these patients, who all had complete or partial
response based on conventional diagnostic methods, those with normalized FDG-
PET scans after two courses of chemotherapy had excellent outcomes, whereas
the failure rate after ASCT in patients with a positive midtreatment PET scan
was 65%. In contrast to FDG-PET defined response, there was no correlation
between the presence or absence of residual tumor mass on midtreatment CT
scan and progression after ASCT. Our pilot study underscores the high per-
formance of FDG-PET as compared with conventional CT scanning for defining
responsive disease and shows promising results of midtreatment FDG-PET in the
prediction of outcome of patients treated for relapsed malignant lymphoma.32,33
The predictive value of early FDG-PET for outcome has been further confirmed
by us and others in relapsed34 as well as in newly diagnosed aggressive lym-
phoma35 and Hodgkin lymphoma.36,37 A prospective, blinded FDG-PET study in
first-line (R)-CHOP treatment in aggressive lymphoma in The Netherlands
(PALET study), has recently been completed and hopefully can validate the pre-
dictive value of midtreatment FDG-PET in front-line treatment of diffuse large
B-cell lymphoma more precisely.
Based on these data, future treatment, at least for patients with relapsed
DLBCL, will be based on FDG-PET-defined response criteria. For instance,
patients with FDG-PET positive lesions after salvage treatment, and those with
insufficient midtreatment FDG-PET-defined response, might be candidates for
more intensive myeloablative treatment, or salvage therapy containing new treat-
ment modalities, respectively. In addition, given the high predictive value of
FDG-PET for residual lymphoma after treatment,38 it can be envisaged that also
primary endpoints in future clinical trials will be based on FDG-PET findings
instead of time dependent survival endpoints. This will have important conse-
quences for the design and statistics of new studies in aggressive lymphoma.
Concluding remarks
Considerable improvement in the outcome of patients with poor-risk aggressive
lymphoma has been achieved in the past decade. Major steps forward have been
the development of the IPI and the WHO lymphoma classification based on ‘real’
entities, enabling better comparison and stratification of patients according to
distinct histologies and clinical risk. The use of G-CSF has enabled dose-dense
6  Summary and general discussion
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treatment strategies and harvesting of stem cells from the peripheral blood for
myeloablative therapy with ASCT. The introduction of rituximab has already
dramatically changed treatment of CD20 positive B-cell lymphoma, but has only
heralded the arrival of a large array of new treatment modalities based on com-
binations of chemotherapy, immunotherapy, immunotherapy conjugates, and
stem cell support. These modalities need careful clinical studies in close coop-
eration between the pharmaceutical companies that provide these new modali-
ties and the clinical investigators. FDG-PET has substantially improved staging
and treatment evaluation and will rapidly become an important tool to guide
treatment early after the start of therapy. Biological studies on tumor material
from uniformly treated patients with homogeneous clinical risk scores will enable
the detection of clinically relevant (sub) groups of lymphoma with different prog-
nosis, possibly in need of new treatment strategies. Future clinical studies will
have to be coupled prospectively to biological side studies. Obtaining fresh tumor
material and creating tissue microarrays for ancillary biological studies will
become mandatory for future clinical studies in malignant lymphoma. This and
future research in lymphoma has been, and will only be possible in the context
of a multicenter cooperative structure, such as HOVON, enabling research by
providing a forum for investigators with new ideas, serving as a robust research
partner for pharmaceutical companies with investigational drugs, and last but
not least obtaining sufficient financial support for conducting prospective clini-
cal studies.
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